Insider Selling: Enanta Pharmaceuticals CEO Unloads 5,800 Shares of Stock (ENTA)
Enanta Pharmaceuticals (NASDAQ:ENTA) CEO Jay R. Luly sold 5,800 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $38.10, for a total transaction of $220,980.00. Following the completion of the transaction, the chief executive officer now directly owns 569,338 shares of the company’s stock, valued at approximately $21,691,778. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 1.05% on Friday, hitting $38.58. 187,067 shares of the company’s stock traded hands. Enanta Pharmaceuticals has a 1-year low of $14.31 and a 1-year high of $40.45. The stock’s 50-day moving average is $33.11 and its 200-day moving average is $24.91. The company’s market cap is $692.9 million.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Thursday, February 13th. The company reported ($0.30) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.15) by $0.15. The company had revenue of $0.89 million for the quarter, compared to the consensus estimate of $1.41 million. On average, analysts predict that Enanta Pharmaceuticals will post $1.20 earnings per share for the current fiscal year.
ENTA has been the subject of a number of recent research reports. Analysts at Credit Suisse raised their price target on shares of Enanta Pharmaceuticals from $36.00 to $43.00 in a research note on Monday. Separately, analysts at Robert W. Baird initiated coverage on shares of Enanta Pharmaceuticals in a research note on Monday, January 27th. They set an “outperform” rating and a $41.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Wednesday, January 1st. They now have a $33.30 price target on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $39.10.
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.